Accolade (Accolade) Change In Receivables : $-1.4 Mil (TTM As of Nov. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Accolade Change In Receivables?

Accolade's change in receivables for the quarter that ended in Nov. 2023 was $-0.2 Mil. It means Accolade's Accounts Receivable increased by $0.2 Mil from Aug. 2023 to Nov. 2023 .

Accolade's change in receivables for the fiscal year that ended in Feb. 2023 was $4.1 Mil. It means Accolade's Accounts Receivable declined by $4.1 Mil from Feb. 2022 to Feb. 2023 .

Accolade's Accounts Receivable for the quarter that ended in Nov. 2023 was $23.2 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Accolade's Days Sales Outstanding for the three months ended in Nov. 2023 was 21.30.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Accolade's liquidation value for the three months ended in Nov. 2023 was $-103.3 Mil.

Accolade Change In Receivables Historical Data

The historical data trend for Accolade's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Accolade Change In Receivables Chart

Accolade Annual Data

Trend

Feb18

Feb19

Feb20

Feb21

Feb22

Feb23

Change In Receivables

Get a 7-Day Free Trial

6.52

-0.68

-10.65

-11.83

4.11

Accolade Quarterly Data
	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23
Change In Receivables	Get a 7-Day Free Trial															6.42	-2.51	0.40	0.99	-0.24

Accolade Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Nov. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.4 Mil.

Accolade (NAS:ACCD) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accolade's Days Sales Outstanding for the quarter that ended in Nov. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	23.195	/	99.371	*	91
=	21.30

2. In Ben Graham's calculation of liquidation value, Accolade's accounts receivable are only considered to be worth 75% of book value:

Accolade's liquidation value for the quarter that ended in Nov. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	230.017	-	350.752	+	0.75 * 23.195	+	0.5 * 0
=	-103.3

Accolade Change In Receivables Related Terms

Thank you for viewing the detailed overview of Accolade's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Accolade (Accolade) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Accolade Inc (NAS:ACCD) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

4NE1:Germany

Address

1201 Third Avenue, Suite 1700, Seattle, WA, USA, 98101

Website

https://www.accolade.com

Accolade Inc offers technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits. It generates revenue by providing personalized health guidance solutions to members.

Executives

Richard Eskew	officer: EVP General Counsel	C/O ACCOLADE, INC., 660 WEST GERMANTOWN PIKE, SUITE 500, PLYMOUTH MEETING PA 19462
Stephen H. Barnes	officer: Chief Financial Officer	C/O ACCOLADE, INC., 660 WEST GERMANTOWN PIKE, SUITE 500, PLYMOUTH MEETING PA 19462
Rajeev Singh	director, officer: Chief Executive Officer	6222 185TH AVENUE NE, REDMOND WA 98052
Robert N Cavanaugh	officer: President	1601 CLOVERFIELD BLVD., SUITE 620, SANTA MONICA CA 90404
Mchugh Colin	officer: Chief Accounting Officer	C/O ACCOLADE, INC., 660 W. GERMANTOWN PIKE, SUITE 500, PLYMOUTH MEETING PA 19462
Michael W Hilton	officer: Chief Product Officer	6222 185TH AVE, REDMOND WA 98052
Peter S Klein	director	C/O MICROSOFT CORPORATION, ONE MICROSOFT WAY, REDMOND WA 98052-6399
Cindy Kent	director	7601 PENN AVENUE SOUTH, RICHFIELD MN 55418
Patricia L Wadors	director	C/O ALIGN TECHNOLOGY INC, 881 MARTIN AVE, SANTA CLARA CA 95050
Dawn G Lepore	director	1425 BROADWAY PMB 41, SEATTLE WA 99122
Jeffrey D Jordan	director	2865 SAND HILL ROAD #101, MENLO PARK CA 94025
Elizabeth G Nabel	director	BRIGHAM AND WOMEN'S HOSPITAL, 75 FRANCIS ST, BOSTON MA 02115
Jeffrey S Brodsky	director	C/O MORGAN STANLEY 1585 BROADWAY, NEW YORK NY 10036
Thomas J Neff	director	SPENCER STUART & ASSOCIATES, 277 PARK AVE, NEW YORK NY 10172
William H. Frist	director	600 MONTGOMERY STREET, SAN FRANCISCO CA 94111